Strs Ohio Acquires 2,900 Shares of Madrigal Pharmaceuticals Inc (MDGL)
Strs Ohio increased its holdings in shares of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) by 241.7% in the 4th quarter, Holdings Channel reports. The firm owned 4,100 shares of the biopharmaceutical company’s stock after acquiring an additional 2,900 shares during the period. Strs Ohio’s holdings in Madrigal Pharmaceuticals were worth $376,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Madrigal Pharmaceuticals during the third quarter worth $100,000. New York State Common Retirement Fund acquired a new position in Madrigal Pharmaceuticals during the second quarter worth $109,000. California State Teachers Retirement System acquired a new position in Madrigal Pharmaceuticals during the second quarter worth $117,000. TIAA CREF Investment Management LLC acquired a new position in Madrigal Pharmaceuticals during the second quarter worth $120,000. Finally, Bank of New York Mellon Corp acquired a new stake in Madrigal Pharmaceuticals in the second quarter valued at $179,000. Institutional investors and hedge funds own 21.71% of the company’s stock.
A number of analysts have commented on the stock. BidaskClub upgraded shares of Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 20th. HC Wainwright assumed coverage on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 29th. They issued a “buy” rating and a $54.00 price target for the company. Evercore ISI increased their price target on shares of Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, December 7th. Roth Capital set a $82.00 price target on shares of Madrigal Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 30th. Finally, Zacks Investment Research upgraded shares of Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $154.20.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.11. equities analysts expect that Madrigal Pharmaceuticals Inc will post -2.57 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Strs Ohio Acquires 2,900 Shares of Madrigal Pharmaceuticals Inc (MDGL)” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://theolympiareport.com/2018/02/12/strs-ohio-acquires-2900-shares-of-madrigal-pharmaceuticals-inc-mdgl.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.